Physician profile
Sara Elizabeth Nashi
NPI 1699087080
$115,803.69
in general payments reported to CMS, 2019-2025
24 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,924 · 2020: $627 · 2021: $2,667 · 2022: $11K · 2023: $32K · 2024: $38K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Food and Beverage: $8,157 · Travel and Lodging: $8,137 · Consulting Fee: $2,638 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,543.75 |
| Food and Beverage | $8,157.14 |
| Travel and Lodging | $8,136.72 |
| Consulting Fee | $2,637.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $515.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $101,405.50 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, General - Therapies |
| Abbott Laboratories | $6,608.59 | 2019-2025 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $2,553.46 | 2022-2023 | Intracept |
| Medtronic USA, INC. | $1,083.40 | 2019 | |
| Spr Therapeutics, INC | $770.67 | 2019-2025 | Sprint Pns System |
| Nevro Corp. | $673.48 | 2019-2023 | Senza |
| Abbvie INC. | $613.92 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Vertos Medical, INC. | $428.18 | 2021-2023 | Mild Device Kit |
| Saluda Medical Americas, INC. | $328.25 | 2023-2025 | Evoke, Evoke Scs |
| Si-Bone, INC. | $308.06 | 2024-2025 | |
| Globus Medical, INC. | $303.03 | 2025 | Senza, Vyrsa V1 |
| Medtronic, INC. | $276.62 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Biotronik Nro, INC. | $100.69 | 2025 | Prospera |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertex Pharmaceuticals Incorporated | $55.26 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $43.13 | 2025 | Optablate, Mild Device Kit |
| Grt US Holding, INC. | $38.15 | 2022 | |
| Spinal Simplicity, LLC | $27.67 | 2025 | Ha Minuteman G3-R |
| Bioventus LLC | $18.22 | 2022 | |
| Painteq LLC | $15.63 | 2024 | Painteq |
| Averitas Pharma INC. | $14.80 | 2023 | Qutenza |
| Novartis Pharmaceuticals Corporation | $14.51 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2019 | |
| Ucb, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Nashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.